Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.
Selank vs Semax
Both are Russian-developed peptides registered as medicines in Russia but unapproved in the US and UK. Selank is positioned around anxiety, Semax around cognition and stroke recovery — with evidence bases that largely predate Western-standard trials.
Selank and Semax are usually researched together as the 'Russian nootropic' pair. The practical reality is the same for both: real regulatory approval exists in Russia, but neither is an approved medicine in the US or UK. Products sold in the UK are gray-market; in the US, under an interim HHS policy announced on October 28, 2026 (published in the Federal Register on October 30), state-licensed pharmacies may compound Semax (not Selank), on its own, for intranasal use on an individual prescription. This comparison explains the difference in their intended uses and the shared limits of their evidence.
Related comparison paths
Move from this comparison into the peptide pages and relevant clinic profiles.
| Category | Selank | Semax |
|---|---|---|
| Directory context | Informational clinic and treatment comparison context. | Informational clinic and treatment comparison context. |
| Common goals | Compare how clinics frame suitability, monitoring, and expected use cases. | Compare how clinics frame suitability, monitoring, and expected use cases. |
| Guidance note | Informational listing only; suitability requires clinician review. | Informational listing only; suitability requires clinician review. |
Next step
Compare clinics offering these treatments
Use city pages and peptide-specific pages to move from general research into actual provider shortlists. That usually gives a better buying picture than comparing drug names alone.
US status since October 2026
On October 28, 2026 HHS announced an interim policy, published in the Federal Register on October 30, 2026, under which state-licensed US pharmacies may compound BPC-157, TB-500, Epitalon, Semax, KPV and MOTS-c for an individual prescription, each on its own and only by the routes the policy lists. It is enforcement discretion, not FDA approval, and HHS may revisit it. Selank is not on the policy's list. Our guide to the October 2026 US peptide policy covers its conditions and the route for each listed peptide (checked October 30, 2026). Outside the US, nothing has changed. What each is, the research, side effects and legal status: Semax peptide.
Related clinics
No tagged clinics yet for this comparison pair.
Related goals
Related conditions
Browse city pages
US city pages
For clinics
Are you a clinic?
Get featured on this page and reach patients actively looking for peptide therapy, GLP-1 treatments, recovery support, and longevity care.